Outlook Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Outlook Therapeutics seeks shareholder approval for share issuance, authorized share increase, and a reverse stock split.
NASDAQ
Outlook Therapeutics, Inc. has filed a definitive proxy statement with the SEC, signaling upcoming shareholder matters.
NASDAQ
Outlook Therapeutics, Inc. announces its 2026 Annual Meeting of Stockholders to be held on March 10, 2026, to vote on director elections, auditor ratification, and executive compensation.
NASDAQ
DEF: Outlook Therapeutics Seeks Stockholder Approval for Share Issuance and Authorized Share Increase
Outlook Therapeutics is asking stockholders to approve a convertible note share issuance and an increase in authorized shares at its upcoming annual meeting.
NASDAQ
Outlook Therapeutics is asking stockholders to approve the 2024 Equity Incentive Plan at a special meeting on August 12, 2024, to continue attracting and retaining talent.